Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma

Bešlić, Nermina; Šadija, Amera; Milardović, Renata; Cerić, Timur; Cerić, Šejla; Beganović, Adnan; Kristić, Spomenka; Čavaljuga, Semra

doi:10.5455/aim.2016.24.99-102

Cited by 9 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more accurate staging with combination of FDG-PET and CT scan can have on impact on the survival rates due to an increased accuracy in mediastinal staging and in the diagnosis of distant metastasis (45,46).…”

Section: Discussionmentioning

confidence: 99%

Surgical approach in oligometastatic non-small cell lung cancer

et al. 2018

View full text Add to dashboard Cite

The vast majority of lung cancer (80%) are non-small cell lung cancer (NSCLC) presenting in huge proportion of patients in a metastatic stage at the time of diagnosis with an overall survival (OS) of only 6 months. Standard treatment at this stage involves systemic platinum based chemotherapy improving the OS for only few months. For the vast majority of patients disease progression occurs and cure cannot achieved. An exception to this general rule is represented by patients with a limited number of metastasis (approximately 7% of patients with metastatic NSCLC): in 1995 Hellman and Weichselbaum introduced the term "oligometastatic" for a selected group of patients with metastatic disease. Several retrospective studies have been published and documented an improved outcome in patients managed surgically. The purpose of this narrative review is to gather all relevant information and present the various clinicopathological and generic aspects of diagnosis, management strategies and prognostic factors in patients with oligometastatic NSCLC. The key for long term survival includes radical treatment of the primary NSCLC, single organ site with either synchronous or metachronous presentation, a disease free interval to be as long as possible and the absence of intrathoracic lymph node spread (N0). A more accurate staging with combination of FDG-PET and CT scan can have on impact on the survival rates due to an increased accuracy in mediastinal staging and in the diagnosis of distant metastasis. No randomized data but only retrospective series are available to date to address this topic: in the future, additional prospective studies will be necessary to provide robust evidence to support the surgical resection as treatment of oligometastatic NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Surgical approach in oligometastatic non-small cell lung cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…was the observation that 15 patients (24%) in this group who were suspected to have relapsed by conventional imaging subsequently received no active treatment after a negative PET-CT. Only 1 of these patients had relapse confirmed on follow-up. By preventing treatment in these patients, PET is likely to have reduced expenditure but also spared these patients unwarranted toxicity ( 17 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

Value of Positron Emission Tomography/Computed Tomography (PET-CT) in Suspected Non-small Cell Lung Cancer Recurrence and Impact on Patient Management

et al. 2016

Self Cite

View full text Add to dashboard Cite

Introduction: Positron emission tomography/computed tomography (PET-CT) is very sensitive for diagnosis of recurrent NSCLC and has a significant impact on change of management. Preliminary data suggest superiority of PET-CT comparing to CT alone for lung cancer restaging. Materials and methods:This is a retrospective study which aim is to validate usage of PET-CT in suspected non-small cell lung carcinoma recurrence and its impact on further patient management. Total number of 31 patients with non-small cell lung carcinoma and uncertain diagnosis of recurrent disease or its extent after routine clinical and CT work-up were enrolled in this study. Discussion: We found in our study that PET-CT diagnosed recurrent disease in 65% of patients who were previously presented with an indeterminante CT.In 85% of patients there were change in further management. Conclusion: We suggest that PET should be performed on patients who have suspected relapse after potentially curative treatment, particularly if active treatment is being considered. PET-CT improved the diagnosis of recurrent NSCLC and this resulted in a significant impact and change in further patient management.

show abstract

“…Mean while, we have seen the new ad vancements in the di ag nos tic and the ther a peu tic use of the ion is ing ra di a tion. At the end of 2013, the Clin i cal Centre of Sarajevo Uni ver sity be gan per form ing the PET di ag nos tic pro ce dures and the ab la tive radioiodine therapy [43][44][45]. On the other hand, the num ber of pro cedures in the interventional car di ol ogy has been in creasing ever since -in the Clin i cal Cen tre of Sarajevo Uni ver sity, as well as in other hos pi tals in BIH [17].…”

Section: Fig Ure 4 the Av Er Age An Nual Ef Fec Tive Dose In (A) DI mentioning

confidence: 99%

Fifteen years of occupational exposure monitoring in the Federation of Bosnia and Herzegovina

et al. 2018

Self Cite

View full text Add to dashboard Cite

The per sonal do sim e try in Bosnia and Herzegovina started in 1960. Af ter a brief in ter rup tion in 1990s, the do sim e try ser vice re sumed in 1999. Un til 2013, the Ra di a tion Pro tec tion Centre of the In sti tute of Pub lic Health of Fed er a tion of Bosnia and Herzegovina has been the only in sti tu tion in the coun try that could pro vide this ser vice. In 2013, this Center cov ered more than 70 % (1,485) of all ra di a tion work ers in the coun try. They mostly worked in med ical in sti tu tions (1,417 or 95.4 %), while oth ers are ex posed to ra di a tion sources in in dus try and vet er i nary ra di ol ogy. From 1999 to 2013, the ma jor ity of an nual doses were less than 1 mSv (96.2 %). There are no reg is tered cases of ex ceed ing the an nual dose limit (20 mSv). The re sults anal y sis shows the re duc tion of in di vid ual doses in last five years. Newly adopted prac tices in med i cine, such as the pos i tron emis sion to mog ra phy, could cause the in crease of doses in the years to come.

show abstract

Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma

Cited by 9 publications

References 18 publications

Surgical approach in oligometastatic non-small cell lung cancer

Surgical approach in oligometastatic non-small cell lung cancer

Value of Positron Emission Tomography/Computed Tomography (PET-CT) in Suspected Non-small Cell Lung Cancer Recurrence and Impact on Patient Management

Fifteen years of occupational exposure monitoring in the Federation of Bosnia and Herzegovina

Contact Info

Product

Resources

About